

**A Declaration of Joint Working Between**  
AstraZeneca UK Limited,  
Aneurin Bevan University health Board

Aneurin Bevan UHB and AstraZeneca UK Limited are engaged in a Joint Working Agreement called "**Aneurin Bevan 'Severe Asthma Pathway Resource'**". This project will run from 15th November 2023 to September 2025 and both parties have contributed resources to this initiative.

The overall aim of this Joint Working Agreement is to optimize the identification and management of Severe asthma in primary and secondary care.

It is expected that this Joint Working Agreement will increase identification of suspected severe asthma patients, and increase the number of suspected Severe Asthma patient reviews, resulting in improvement in symptoms and/or ACQ score and reducing time to MDT and/or appropriate treatment.

The objectives of this project are:

- Increased proportion of suspected SA proactively identified.
- Increased number of appropriate new patients being reviewed.
- Increased number of patients referred to specialist MDT.
- Increased number of new biologics starts where appropriate to do so.
- Reduction in OCS use amongst identified patients.